A top FDA official is advocating for increased government oversight of vaccines, signaling a potential shift in the agency’s approach to approvals. This call for tighter regulation follows an internal review that has linked COVID-19 vaccines to the deaths of ten children, raising concerns about vaccine safety and efficacy within the agency.
The proposed changes could include stricter guidelines for the annual flu shot and the evaluation process for new vaccines. This move comes amid ongoing debates about vaccine mandates and the role of government in public health decisions. The FDA’s internal findings have added fuel to the fire, prompting calls for greater transparency and accountability.
If implemented, these stricter guidelines could significantly impact the vaccine development and approval process, potentially leading to longer timelines and increased costs for manufacturers. The changes could also affect public confidence in vaccines, particularly if the FDA’s review is perceived as an admission of past failures or oversights in vaccine safety protocols.
